Negative parkinsonian, depressive and catatonic symptoms in schizophrenia: a conflict of paradigms revisited
- PMID: 10638863
- DOI: 10.1016/s0920-9964(99)00047-x
Negative parkinsonian, depressive and catatonic symptoms in schizophrenia: a conflict of paradigms revisited
Abstract
Background: To study the interrelationship pattern of negative, depressive, parkinsonian and catatonic symptoms over an exacerbation phase of schizophrenia.
Method: Forty-five inpatients with a DSM-IV diagnosis of schizophrenia or schizophreniform disorder were assessed at admission and discharge for negative, depressive, parkinsonian and catatonic symptoms. A subsample of patients unmedicated at admission (n=23) was specifically analyzed.
Results: Negative, parkinsonian and catatonic symptoms correlated significantly at both assessment points, as did their mean changes over the episode. At admission, depressive symptoms did not correlate with negative, parkinsonian or catatonic symptoms, but they did at discharge. Changes of depressive symptoms over the episode did not correlate with changes of the other groups of symptoms. In the patients who were unmedicated at admission, ratings of nonakinetic parkinsonism, unlike ratings of akinetic parkinsonism, worsened significantly after neuroleptic treatment.
Conclusions: While negative, parkinsonian and catatonic symptoms are highly related features, depressive symptoms seem to be a relatively independent dimension of psychopathology in schizophrenia. Non-akinetic parkinsonian symptoms may be more useful than the akinetic symptoms in distinguishing primary from drug-induced negative symptoms.
Similar articles
-
Differentiating primary from secondary negative symptoms in schizophrenia: a study of neuroleptic-naive patients before and after treatment.Am J Psychiatry. 2000 Sep;157(9):1461-6. doi: 10.1176/appi.ajp.157.9.1461. Am J Psychiatry. 2000. PMID: 10964863
-
Depression, parkinsonian symptoms, and negative symptoms in schizophrenics treated with neuroleptics.J Nerv Ment Dis. 1987 Feb;175(2):100-5. doi: 10.1097/00005053-198702000-00006. J Nerv Ment Dis. 1987. PMID: 2879880
-
Depression during an acute episode of schizophrenia or schizophreniform disorder and its impact on treatment response.Psychiatry Res. 2008 Apr 15;158(3):297-305. doi: 10.1016/j.psychres.2007.01.002. Epub 2008 Feb 15. Psychiatry Res. 2008. PMID: 18280582 Clinical Trial.
-
Deficit symptoms in schizophrenia: negative symptoms versus neuroleptic-induced deficits.Acta Psychiatr Scand Suppl. 1994;380:21-6. doi: 10.1111/j.1600-0447.1994.tb05827.x. Acta Psychiatr Scand Suppl. 1994. PMID: 7914043 Review.
-
[Changes to Schizophrenia Spectrum and other psychotic disorders in DSM-5].Z Kinder Jugendpsychiatr Psychother. 2014 May;42(3):193-202. doi: 10.1024/1422-4917/a000289. Z Kinder Jugendpsychiatr Psychother. 2014. PMID: 24846868 Review. German.
Cited by
-
Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo-controlled study in healthy volunteers.Psychopharmacology (Berl). 2011 Dec;218(4):733-48. doi: 10.1007/s00213-011-2368-3. Epub 2011 Jun 4. Psychopharmacology (Berl). 2011. PMID: 21643673 Clinical Trial.
-
Obstetric complications and neurological abnormalities in neuroleptic-naive psychotic patients.Eur Arch Psychiatry Clin Neurosci. 2006 Oct;256(7):407-13. doi: 10.1007/s00406-006-0653-7. Epub 2006 Jun 20. Eur Arch Psychiatry Clin Neurosci. 2006. PMID: 16788770
-
Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms.Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD013100. doi: 10.1002/14651858.CD013100.pub2. Cochrane Database Syst Rev. 2022. PMID: 35844143 Free PMC article.
-
The effect of antipsychotic medication on neuromotor abnormalities in neuroleptic-naive nonaffective psychotic patients: a naturalistic study with haloperidol, risperidone, or olanzapine.Prim Care Companion J Clin Psychiatry. 2010;12(2):PCC.09m00799. doi: 10.4088/PCC.09m00799gry. Prim Care Companion J Clin Psychiatry. 2010. PMID: 20694120 Free PMC article.
-
A case of schizophrenia with relapsed catatonia successfully treated with blonanserin transdermal patch.Neuropsychopharmacol Rep. 2023 Mar;43(1):150-153. doi: 10.1002/npr2.12314. Epub 2023 Jan 18. Neuropsychopharmacol Rep. 2023. PMID: 36651841 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical